Accéder au contenu
Merck

The Borrelia burgdorferi VlsE Lipoprotein Prevents Antibody Binding to an Arthritis-Related Surface Antigen.

Cell reports (2020-03-19)
Abdul G Lone, Troy Bankhead
RÉSUMÉ

Arp is an immunogenic protein of the Lyme disease spirochete Borrelia burgdorferi and contributes to joint inflammation during infection. Despite Arp eliciting a strong humoral response, antibodies fail to clear the infection. Given previous evidence of immune avoidance mediated by the antigenically variable lipoprotein of B. burgdorferi, VlsE, we use passive immunization assays to examine whether VlsE protects the pathogen from anti-Arp antibodies. The results show that spirochetes are only able to successfully infect passively immunized mice when VlsE is expressed. Subsequent immunofluorescence assays reveal that VlsE prevents binding of Arp-specific antibodies, thereby providing an explanation for the failure of Arp antisera to clear the infection. The results also show that the shielding effect of VlsE is not universal for all B. burgdorferi cell-surface antigens. The findings reported here represent a direct demonstration of VlsE-mediated protection of a specific B. burgdorferi surface antigen through a possible epitope-shielding mechanism.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Méthanol, suitable for HPLC, ≥99.9%
Sigma-Aldrich
Kanamycine sulfate from Streptomyces kanamyceticus, powder, BioReagent, suitable for cell culture, suitable for plant cell culture
Sigma-Aldrich
Rifampicine, ≥95% (HPLC), powder or crystals
Sigma-Aldrich
TiterMax® Gold Adjuvant, liquid
Sigma-Aldrich
1-Butyl-3-methylimidazolium hexafluorophosphate, ≥97.0% (HPLC)
Sigma-Aldrich
Triton X-114, laboratory grade
Supelco
Protein Standard, analytical standard, 200 mg/mL (BSA)